Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer
International Journal of Colorectal Disease · 2024
DOI: 10.1007/s00384-024-04767-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2024. Verfasst von Kuan-Yu Tseng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Bevacizumab, Trifluridine, Thymine, Colorectal Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Taipei, 11217, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Division of Medical Education, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Colon and Rectum Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Taipei, 11217, Taiwan. hwteng1971@gmail.com.
Zitieren
APA
Tseng, K. Y., Yang, M. Y., Chen, W. S., Jiang, J. K., Wang, H. S., Chang, S. C., Lan, Y. T., Lin, C. C., Lin, H. H., Huang, S. C., Cheng, H. H., Yang, Y. W., Lin, Y. Z., Chang, C. Y., & Teng, H. W. (2024). Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-024-04767-9
Vancouver
Tseng KY, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, et al. Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer. International Journal of Colorectal Disease. 2024. doi:10.1007/s00384-024-04767-9
BibTeX
@article{Tseng2024,
author = {Tseng, Kuan-Yu and Yang, Mu-Ying and Chen, Wei-Shone and Jiang, Jeng-Kai and Wang, Huann-Sheng and Chang, Shih-Ching and Lan, Yuan-Tzu and Lin, Chun-Chi and Lin, Hung-Hsin and Huang, Sheng-Chieh and Cheng, Hou-Hsuan and Yang, Yi-Wen and Lin, Yu-Zu and Chang, Che-Yuan and Teng, Hao-Wei},
title = {Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer},
journal = {International Journal of Colorectal Disease},
year = {2024},
doi = {10.1007/s00384-024-04767-9}
}
EUVIMED